Sign up
Pharma Capital

Paradigm Biopharmaceuticals in a trading halt as news pending

The halt will remain in place until Monday 19th June 2017.
Paradigm is a biopharmaceutical company

Paradigm Biopharmaceuticals (ASX:PAR) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Paradigm requested the halt pending the company reviewing the status of its current clinical trial in allergic rhinitis.

The halt will remain in place until the opening of trade on Monday 19th June 2017, or earlier if an announcement is made to the market.

View full PAR profile

Paradigm Biopharmaceuticals Ltd Timeline

View All

Related Articles

US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.